Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin

American Journal of Health-System Pharmacy

Volumn 59, Issue 13, 2002, Pages 1258-1266

  Inglis, Anne Marie L ^a   Sheth, Sunita B ^a   Hursting, Marcie J ^a   Tenero, David M ^a   Graham, Alison M ^a   DiCicco, Robert A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Acetaminophen; Analgesics and antipyretics; Anesthetics, local; Anticoagulants; Argatroban; Cardiac drugs; Digoxin; Drug interactions; Lidocaine hydrochloride; Pharmacokinetics

Indexed keywords

ARGATROBAN; DIGOXIN; LIDOCAINE; PARACETAMOL; TYLENOL EXTRA STRENGTH; ANALGESIC AGENT; ANTITHROMBIN; LOCAL ANESTHETIC AGENT; PIPECOLIC ACID DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; MYALGIA; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CONFIDENCE INTERVAL; DRUG INTERACTION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MIDDLE AGED;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; ANESTHETICS, LOCAL; ANTITHROMBINS; AREA UNDER CURVE; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DIGOXIN; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; LIDOCAINE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PIPECOLIC ACIDS;

EID: 0036628640     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.13.1258     Document Type: Article

References (12)

1. Novastan (brand of argatroban) a small-molecule, direct thrombin inhibitor
2. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban
3. Kinetics and metabolism of paracetamol and phenacetin
4. Oxidation of acetaminophen to Nacetyl-p-aminobenzoquinone imine by human CYP3A4
5. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4
6. Pharmacokinetic interactions between digoxin and other drugs
7. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
8. A distribution-free procedure for the statistical analysis of bioequivalence studies
9. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects
10. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
11. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia